Accidents domestiques "46-13/12 alzheimer.

Accidents domestiques.

Bonjour.

46-13/12 alzheimer.

Références

Note : les liens hypertextes menant vers d’autres sites ne sont pas mis à jour de façon continue. Il est possible qu’un lien devienne introuvable. Veuillez alors utiliser les outils de recherche pour retrouver l’information désirée.

Bibliographie

Arcand et Hébert (dir). Précis pratique de gériatrie, Éditions Edisem, Canada, 2007.
Burgener SC, Buettner L, et al. Evidence supporting nutritional interventions for persons in early stage Alzheimer’s disease (AD). J Nutr Health Aging. 2008 Jan;12(1):18-21. Review.
InteliHealth (Ed). Health A-Z - Alzheimer’s Disease, Aetna Intelihealth. [Consulté le 18 novembre 2010]. www.intelihealth.com
Mayo Foundation for Medical Education and Research (Ed). Diseases & Conditions - Alzheimer’s Disease, MayoClinic.com. [Consulté le 18 novembre 2010]. www.mayoclinic.com
Micromedex Healthcare Series. Micromedex Inc., Englewood, Colorado.
National Library of Medicine (Ed). PubMed, NCBI. [Consulté le 18 novembre 2010]. www.ncbi.nlm.nih.gov
Pizzorno JE Jr, Murray Michael T (Ed). Textbook of Natural Medicine, Churchill Livingstone, États-Unis, 2006.
Société Alzheimer du Canada (Ed). [Consulté le 18 novembre 2010]. www.alzheimer.ca
The Natural Pharmacist (Ed). Natural Products Encyclopedia, Conditions – Alzheimer’s Disease and Non-Alzheimer’s Dementia, ConsumerLab.com. [Consulté le 18 novembre 2010]. www.consumerlab.com
UpToDate. Patient information: Dementia (including Alzheimer disease). [Consulté le 16 novembre 2010]. www.uptodate.com.Alzheimer disease. Castellani RJ, Rolston RK, Smith MA. Dis Mon. 2010 Sep;56(9):484-546. Review.
Can Alzheimer’s disease be prevented ? US Department of Health and human services. National Institutes of Health, National Institute on Aging. NIH Publication No 09-5503. April 2009.Alternative medicine and Alzheimer disease. Kelley BJ, Knopman DS. Neurologist. 2008 Sep;14(5):299-306. Review.

Notes

1. Ferreira PC, Piai Kde A, et al. Aluminum as a risk factor for Alzheimer’s disease. Rev Lat Am Enfermagem. 2008 Jan-Feb;16(1):151-7. Review. Texte intégral : www.scielo.br
2. Maladie d’Alzheimer et maladies apparentées : vers un diagnostic plus précis et précoce. M.-P. Fortin, P. Krolak-Salmon. La Revue de Médecine Interne. En ligne en octobre 2010.
3. Alzheimer's Association Report. 2010 Alzheimer'snext term disease facts and figures. Alzheimer's and Dementia. Volume 6, Issue 2, March 2010, Pages 158-194.
4. Mediterranean diet and cognitive function in older adults. Féart C, Samieri C, Barberger-Gateau P. Curr Opin Clin Nutr Metab Care. 2010 Jan;13(1):14-8. Review.
5. Neuronutrition and Alzheimer's disease. Ramesh BN, Rao TS, Prakasam A, et al. J Alzheimers Dis. 2010;19(4):1123-39. Review.
6. Ray S, Britschgi M, et al. Classification and prediction of clinical Alzheimer’s diagnosis based on plasma signaling proteins. Nat Med. 2007 Nov;13(11):1359-62. Epub 2007 Oct 14.
7. Scarmeas N, Stern Y, et al. Mediterranean diet and risk for Alzheimer’s disease. Ann Neurol. 2006 Jun;59(6):912-21.
8. Scarmeas N, Luchsinger JA, et al. Mediterranean diet and Alzheimer disease mortality. Neurology. 2007 Sep 11;69(11):1084-93.
9. Burgener SC, Buettner L, et al. Evidence supporting nutritional interventions for persons in early stage Alzheimer’s disease (AD). J Nutr Health Aging. 2008 Jan;12(1):18-21. Review.
10. Esposito E, Rotilio D, et al. A review of specific dietary antioxidants and the effects on biochemical mechanisms related to neurodegenerative processes. Neurobiol Aging. 2002 Sep-Oct;23(5):719-35. Review.
11. Salerno-Kennedy R, Cashman KD. Relationship between dementia and nutrition-related factors and disorders: an overview. Int J Vitam Nutr Res. 2005 Mar;75(2):83-95. Review.
12. Luchsinger JA, Tang MX, Shea S, Mayeux R. Caloric intake and the risk of Alzheimer disease. Arch Neurol. 2002 Aug;59(8):1258-63.
13. Mattson MP. Neuroprotective signaling and the aging brain: take away my food and let me run. Brain Res. 2000 Dec 15;886(1-2):47-53. Review.
14. Unverzagt FW, Kasten L, et al. Effect of memory impairment on training outcomes in ACTIVE. J Int Neuropsychol Soc. 2007 Nov;13(6):953-60.
15. Lemonick MD, Park A. The Nun Study. How one scientist and 678 sisters are helping unlock the secrets of Alzheimer’s. Time 2001 May 14;157(19):54-9, 62, 64.
16. Effect of physical activity on cognitive function in older adults at risk for Alzheimer disease: a randomized trial. Lautenschlager NT, Cox KL, Flicker L, et al. JAMA. 2008 Sep 3;300(9):1027-37. Erratum in: JAMA. 2009 Jan 21;301(3):276.
17. Mayo Foundation for Medical Education and Research (Ed). Diseases & Conditions, Alzheimer’s Disease, Caregiving for Alzheimer’s - Benefits of exercise for Alzheimer’s, MayoClinic.com. [Consulté le 14 novembre 2001]. www.mayoclinic.com
18. Promising strategies for the prevention of dementia. Middleton LE, Yaffe K. Arch Neurol. 2009 Oct;66(10):1210-5. Review.
19. Panza F, Solfrizzi V, et al. Mediterranean diet and cognitive decline. Public Health Nutr. 2004 Oct;7(7):959-63.
20. Larrieu S, Letenneur L, et al. Nutritional factors and risk of incident dementia in the PAQUID longitudinal cohort. J Nutr HealthAging. 2004;8(3):150-4.
21. Morris MC, Evans DA, et al. Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease. Arch Neurol. 2003 Jul;60(7):940-6.
22. Solfrizzi V, Panza F, Capurso A. The role of diet in cognitive decline. J Neural Transm. 2003 Jan;110(1):95-110. Review.
23. Cognitive performance among the elderly and dietary fish intake: the Hordaland Health Study. Nurk E, Drevon CA, Refsum H, et al. Am J Clin Nutr. 2007 Nov;86(5):1470-8.
24. Kalmijn S. Fatty acid intake and the risk of dementia and cognitive decline: a review of clinical and epidemiological studies. J Nutr Health Aging. 2000;4(4):202-7. Review.
25. Kalmijn S, van Boxtel MP, et al. Dietary intake of fatty acids and fish in relation to cognitive performance at middle age.Neurology. 2004 Jan 27;62(2):275-80.
26. Conquer JA, Tierney MC, et al. Fatty acid analysis of blood plasma of patients with Alzheimer’s disease, other types of dementia, and cognitive impairment. Lipids. 2000 Dec;35(12):1305-12.
27. Heude B, Ducimetiere P, Berr C; EVA Study. Cognitive decline and fatty acid composition of erythrocyte membranes--The EVA Study. Am J Clin Nutr. 2003 Apr;77(4):803-8. Texte intégral [Consulté le 28 novembre 2010] : www.ajcn.org
28. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. Quinn JF, Raman R, Thomas RG, et al. JAMA. 2010 Nov 3;304(17):1903-11.
29. Low plasma N-3 fatty acids and dementia in older persons: the InCHIANTI study. Cherubini A, Andres-Lacueva C, Martin A, et al. J Gerontol A Biol Sci Med Sci. 2007 Oct;62(10):1120-6.
30. Update on the pharmacological treatment of Alzheimer's disease. Massoud F, Gauthier S. Curr Neuropharmacol. 2010 Mar;8(1):69-80.
31. Birks J, Grimley EV, Van Dongen M. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev. 2002;(4):CD003120. Review.
32. Wettstein A. Cholinesterase inhibitors and Gingko extracts--are they comparable in the treatment of dementia? Comparison of published placebo-controlled efficacy studies of at least six months’ duration. Phytomedicine 2000 Jan;6(6):393-401.
33. Schreiter Gasser U, Gasser T. [A comparison of cholinesterase inhibitors and ginkgo extract in treatment of Alzheimer dementia] [Article in German]. Fortschr Med Orig 2001 Nov 29;119(3-4):135-8.
34. Zoller B, Hock C, Kull HU. [Rational therapy of Alzheimer dementia based on current clinical studies] [Article in German]. Schweiz Rundsch Med Prax 2001 May 10;90(19):827-34.
35. Kurz A, Van Baelen B. Ginkgo biloba compared with cholinesterase inhibitors in the treatment of dementia: a review based on meta-analyses by the Cochrane collaboration. Dement Geriatr Cogn Disord. 2004;18(2):217-26.
36. Xu SS, Gao ZX, et al. Efficacy of tablet huperzine-A on memory, cognition, and behavior in Alzheimer’s disease.Zhongguo Yao Li Xue Bao 1995;16(5):391-5.
37. Zhang Z, Wang X, et al. [Clinical efficacy and safety of huperzine Alpha in treatment of mild to moderate Alzheimer disease, a placebo-controlled, double-blind, randomized trial] [Article in Chinese]. Zhonghua Yi Xue Za Zhi 2002 Jul 25;82(14):941-4.
38. Xu SS, Cai ZY, et al. Huperzine-A in capsules and tablets for treating patients with Alzheimer disease. Zhongguo Yao Li Xue Bao 1999 Jun;20(6):486-90.
39. Zhang Z, Wang X, et al. [Clinical efficacy and safety of huperzine Alpha in treatment of mild to moderate Alzheimer disease, a placebo-controlled, double-blind, randomized trial]. [Article en chinois, résumé en anglais]. Zhonghua Yi Xue Za Zhi. 2002 Jul 25;82(14):941-4.
40. Wang R, Yan H, Tang XC. Progress in studies of huperzine A, a natural cholinesterase inhibitor from Chinese herbal medicine. Acta Pharmacol Sin. 2006 27:1-26. Extraits du texte intégral : www.chinaphar.com
41. Snyder M, Chlan L. Music therapy. Annu Rev Nurs Res. 1999;17:3-25.
42. Grasel E, Wiltfang J, Kornhuber J. Non-drug therapies for dementia: an overview of the current situation with regard to proof of effectiveness. Dement Geriatr Cogn Disord. 2003;15(3):115-25.
43. Snowden M, Sato K, Roy-Byrne P. Assessment and treatment of nursing home residents with depression or behavioral symptoms associated with dementia: a review of the literature. J Am Geriatr Soc. 2003;51(9):1305-17.
44. Sherratt K, Thornton A, Hatton C. Music interventions for people with dementia: a review of the literature. Aging Ment Health. 2004;8(1):3-12.
45. Goodall D, Etters L. The therapeutic use of music on agitated behavior in those with dementia. Holist Nurs Pract. 2005;19(6):258-62.
46. Livingston G, Johnston K, et al. Systematic review of psychological approaches to the management of neuropsychiatric symptoms of dementia. Am J Psychiatry. 2005;162(11):1996-2021.
47. Sung HC, Chang AM. Use of preferred music to decrease agitated behaviours in older people with dementia: a review of the literature. J Clin Nurs. 2005;14(9):1133-40.
48. Watson R, Green SM. Feeding and dementia: a systematic literature review. J Adv Nurs. 2006;54(1):86-93.
49. Vink AC, Birks JS, et al. Music therapy for people with dementia. Cochrane Database Syst Rev. 2004(3):CD003477.
50. Scherder EJ, Van Someren EJ, Bouma A, Berg M. Effects of transcutaneous electrical nerve stimulation (TENS) on cognition and behaviour in aging. Behav Brain Res 2000;111:223-225.
51. Scherder EJ, Bouma A, Steen AM. Effects of short-term transcutaneous electrical nerve stimulation on memory and affective behaviour in patients with probable Alzheimer’s disease. Behav Brain Res 1995;67(2):211-219.
52. Guo Y, Shi X, Uchiyama H, Hasegawa A, Nakagawa Y, Tanaka M, Fukumoto I. A study on the rehabilitation of cognitive function and short-term memory in patients with Alzheimer’s disease using transcutaneous electrical nerve stimulation. Front Med Biol Eng. 2002;11(4):237-47.
53. Alternative medicine and Alzheimer disease. Kelley BJ, Knopman DS. Neurologist. 2008 Sep;14(5):299-306. Review.
54. Vinpocetine for cognitive impairment and dementia. Szatmari SZ, Whitehouse PJ. Cochrane Database Syst Rev. 2003;(1):CD003119. Review.
55. Entrevue avec Judes Poirier par Martin LaSalle, journaliste à PasseportSanté.net (28 janvier 2008). www.passeportsante.net
57. Akhondzadeh S, Noroozian M, et al. Salvia officinalis extract in the treatment of patients with mild to moderate Alzheimer’s disease: a double blind, randomized and placebo-controlled trial. J Clin Pharm Ther. 2003 Feb;28(1):53-9.
58. Richeson NE. Effects of animal-assisted therapy on agitated behaviors and social interactions of older adults with dementia. Am J Alzheimers Dis Other Demen. 2003;18(6):353-8.
59. Churchill M, Safaoui J, et al. Using a therapy dog to alleviate the agitation and desocialization of people with Alzheimer’s disease. J Psychosoc Nurs Ment Health Serv. 1999;37(4):16-22.
60. Kongable LG, Buckwalter KC, Stolley JM. The effects of pet therapy on the social behavior of institutionalized Alzheimer’s clients. Arch Psychiatr Nurs. 1989;3(4):191-8.
61. Hudson S, Tabet N. Acetyl-L-carnitine for dementia. Cochrane Database Syst Rev. 2003;(2):CD003158. Review.
62. Montgomery SA, Thal LJ, Amrein R. Meta-analysis of double blind randomized controlled clinical trials of acetyl-L-carnitine versus placebo in the treatment of mild cognitive impairment and mild Alzheimer’s disease. Int Clin Psychopharmacol. 2003 Mar;18(2):61-71.
63. Ono K, Hasegawa K, Naiki H, Yamada M. Curcumin has potent anti-amyloidogenic effects for Alzheimer’s beta-amyloid fibrils in vitro. J Neurosci Res. 2004 Mar 15;75(6):742-50.
64. Yang F, Lim GP, et al. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem. 2005 Feb 18;280(7):5892-901.
65. Park SY, Kim DS. Discovery of natural products from Curcuma longa that protect cells from beta-amyloid insult: a drug discovery effort against Alzheimer’s disease. J Nat Prod. 2002 Sep;65(9):1227-31.
66. Ringman JM, Frautschy SA, Cole GM et al. A potential role of the curry spice curcumin in Alzheimer’s disease. Curr Alzheimer Res. 2005 Apr;2(2):131-6.
67. Holmes C, Hopkins V, et al. Lavender oil as a treatment for agitated behaviour in severe dementia: a placebo controlled study.Int J Geriatr Psychiatry 2002 Apr;17(4):305-8.
68. Gray SG, Clair AA. Influence of aromatherapy on medication administration to residential-care residents with dementia and behavioral challenges. Am J Alzheimers Dis Other Demen. 2002 May-Jun;17(3):169-74.
69. Snow LA, Hovanec L, Brandt J. A controlled trial of aromatherapy for agitation in nursing home patients with dementia. J Altern Complement Med. 2004 Jun;10(3):431-7.
70. Lee SY. [The effect of lavender aromatherapy on cognitive function, emotion, and aggressive behavior of elderly with dementia][Article en coréen, résumé en anglais]. Taehan Kanho Hakhoe Chi. 2005 Apr;35(2):303-12.
71. Kennedy DO, Scholey AB, et al. Modulation of mood and cognitive performance following acute administration of Melissa officinalis (lemon balm). Pharmacol Biochem Behav. 2002 Jul;72(4):953-64.
72. Kennedy DO, Wake G, et al. Modulation of mood and cognitive performance following acute administration of single doses of Melissa officinalis (Lemon balm) with human CNS nicotinic and muscarinic receptor-binding properties. Neuropsychopharmacology. 2003 Oct;28(10):1871-81.
73. Akhondzadeh S, Noroozian M, et al. Melissa officinalis extract in the treatment of patients with mild to moderate Alzheimer’s disease: a double blind, randomised, placebo controlled trial. J Neurol Neurosurg Psychiatry. 2003 Jul;74(7):863-6. Texte intégral : http://jnnp.bmj.com.
74. Pizzorno JE Jr, Murray Michael T (Ed). Textbook of Natural Medicine, Churchill Livingstone, États-Unis, 2006, p. 1463.
75. Fédération québécoise des sociétés Alzheimer. [Consulté 18 novembre 2010]. www.alzheimerquebec.ca
76. Adapté de la documentation de la 2000 Alzheimer Disease and Related Disorders Association ainsi que du World Alzheimer Congress 2000.
78. Boothby LA, Doering PL. Vitamin C and vitamin E for Alzheimer's disease. Ann Pharmacother. 2005 Dec;39(12):2073-80. Review.
79. Pham DQ, Plakogiannis R. Vitamin E supplementation in Alzheimer's disease, Parkinson's disease, tardive dyskinesia, and cataract: Part 2. Ann Pharmacother. 2005 Dec;39(12):2065-72. Review.
80. Miller ER 3rd, Pastor-Barriuso R, et al. Meta-Analysis: High-Dosage Vitamin E Supplementation May Increase All-Cause Mortality. Ann Intern Med. 2004 Nov 10. Texte intégral : www.annals.org
81. Are omega-3 fatty acids options for prevention and treatment of cognitive decline and dementia? Cederholm T, Palmblad J. Curr Opin Clin Nutr Metab Care. 2010 Mar;13(2):150-5. Review.
82. Prevention of age-associated dementia. Mohajeri MH, Leuba G. Brain Res Bull. 2009 Oct 28;80(4-5):315-25. Epub 2009 Jul 1. Review.
83. Omega-3 fatty acids and dementia. Cole GM, Ma QL, Frautschy SA. Prostaglandins Leukot Essent Fatty Acids. 2009 Aug-Sep;81(2-3):213-21. Epub 2009 Jun 12. Review.
84. Omega-3 fatty acids and cognitive function in women. Robinson JG, Ijioma N, Harris W. Womens Health (Lond Engl). 2010 Jan;6(1):119-34. Review.
85. Effects of Ginkgo biloba in dementia: systematic review and meta-analysis. Weinmann S, Roll S, Schwarzbach C, et al. BMC Geriatr. 2010 Mar 17;10:14. Review.
86. Role of huperzine a in the treatment of Alzheimer's disease. Desilets AR, Gickas JJ, Dunican KC. Ann Pharmacother. 2009 Mar;43(3):514-8. Epub 2009 Feb 24. Review.